Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Update of the National Genomic Test Directory in England

19 Jun 2023

On June 1, 2023, NHS England issued an updated version of the National Genomic Test Directory, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Three documents were updated specifying tests codes, clinical indications, target genes, the technology by which tests are available, and eligibility criteria for patients:

  • National Genomic Test Directory for cancer (version 7.1);
  • National Genomic Test Directory for rare and inherited diseases (version 5.1);
  • Rare and inherited disease eligibility criteria (version 5.2).

Three new codes (test-indication combinations) were introduced in the Test Directory for rare and inherited diseases. No new codes were introduced in the Test Directory for cancer.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.